Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma

被引:29
作者
Laver, T. [1 ]
London, C. A. [2 ]
Vail, D. M. [3 ]
Biller, B. J. [1 ]
Coy, J. [1 ]
Thamm, D. H. [1 ,4 ,5 ]
机构
[1] Colorado State Univ, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA
[2] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA
[3] Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA
[4] Colorado State Univ, Cell & Mol Biol Grad Program, Ft Collins, CO 80523 USA
[5] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA
关键词
dog; metastasis; oncology; osteosarcoma; tyrosine kinase; TYROSINE KINASE INHIBITOR; LOW-DOSE CYCLOPHOSPHAMIDE; APPENDICULAR OSTEOSARCOMA; DOGS; CARBOPLATIN; CHEMOTHERAPY; AMPUTATION; RECURRENT; EFFICACY; ADJUVANT;
D O I
10.1111/vco.12328
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Efficacious therapies for measurable metastatic canine osteosarcoma (OSA) are generally lacking. Preliminary retrospective studies suggested that approximately 50% of dogs with measurable metastatic OSA experienced clinical benefit (objective response or clinically meaningful disease stabilisation) following toceranib (TOC) treatment. The purpose of this clinical trial was to prospectively evaluate the clinical outcome following TOC treatment in dogs with measurable pulmonary metastatic OSA. A secondary goal was to identify potential biomarkers of clinical benefit by measuring changes in plasma vascular endothelial growth factor (VEGF) and circulating regulatory T-cell (Treg) percentage. Twenty-two dogs with pulmonary metastasis from appendicular OSA having undergone previous amputation were treated prospectively with TOC. Adverse events (AEs) were common but predominantly low grade. Nine patients were withdrawn from the study prior to the week 8 assessment of response either due to progressive disease (PD), decreased quality of life or owner perceived unacceptable AEs. Of the patients evaluable for disease progression at week 8 (or earlier), 3/17 (17.6 %) had stable disease with the remainder having PD. The median progression-free survival time for all patients was 57 days (range 7-176 days) with a median overall survival time of 89 days (range 7-574 days). Plasma VEGF concentrations were significantly elevated in patients after 4 weeks of TOC treatment, but no changes were observed in percentage of Treg in peripheral blood. Overall, the results of this clinical trial do not support the use of TOC as single agent therapy for canine metastatic OSA.
引用
收藏
页码:E23 / E29
页数:7
相关论文
共 22 条
[2]   Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993) [J].
Bergman, PJ ;
MacEwen, EG ;
Kurzman, ID ;
Henry, CJ ;
Hammer, AS ;
Knapp, DW ;
Hale, A ;
Kruth, SA ;
Klein, MK ;
Klausner, J ;
Norris, AM ;
McCaw, D ;
Straw, RC ;
Withrow, SJ .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 1996, 10 (02) :76-81
[3]   Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose [J].
Bernabe, Luis Feo ;
Portela, Roberta ;
Nguyen, Sandra ;
Kisseberth, William C. ;
Pennell, Michael ;
Yancey, Mark F. ;
London, Cheryl A. .
BMC VETERINARY RESEARCH, 2013, 9
[4]   Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004) [J].
Boston, SE ;
Ehrhart, NP ;
Dernell, WS ;
Lafferty, M ;
Withrow, SJ .
JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2006, 228 (12) :1905-1908
[5]  
Browder T, 2000, CANCER RES, V60, P1878
[6]   Low-Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits Angiogenesis in Dogs with Soft Tissue Sarcoma [J].
Burton, J. H. ;
Mitchell, L. ;
Thamm, D. H. ;
Dow, S. W. ;
Biller, B. J. .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (04) :920-926
[7]   The efficacy of temozolomide for recurrent glioblastoma multiforme [J].
Chen, Chao ;
Xu, Tao ;
Lu, Yicheng ;
Chen, Juxiang ;
Wu, Shenhong .
EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (02) :223-230
[8]  
Coomber BL, 1998, CAN J VET RES, V62, P199
[9]  
Ehrhart N.P., 2013, Withrow MacEwen's Small Animal Clinical Oncology, P463
[10]   Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours [J].
London, C. ;
Mathie, T. ;
Stingle, N. ;
Clifford, C. ;
Haney, S. ;
Klein, M. K. ;
Beaver, L. ;
Vickery, K. ;
Vail, D. M. ;
Hershey, B. ;
Ettinger, S. ;
Vaughan, A. ;
Alvarez, F. ;
Hillman, L. ;
Kiselow, M. ;
Thamm, D. ;
Higginbotham, M. L. ;
Gauthier, M. ;
Krick, E. ;
Phillips, B. ;
LaDue, T. ;
Jones, P. ;
Bryan, J. ;
Gill, V. ;
Novasad, A. ;
Fulton, L. ;
Carreras, J. ;
McNeill, C. ;
Henry, C. ;
Gillings, S. .
VETERINARY AND COMPARATIVE ONCOLOGY, 2012, 10 (03) :194-205